More PRNewswire
View Older Stories View Newer Stories-
Moomoo's Inaugural Global Paper Trading Challenge Concludes with Over 150,000 Participants and Incredible Performance
-
Sovereign Wealth and Public Pension Funds Set to Reshape Private Markets
-
Geopolitics and Generative AI: Will Middle Powers Reshape the Map?
-
Group Elephant business Valcann named Latin America's 'AWS Collaboration Partner of the Year'
-
LG released new version of generative AI, EXAONE 3.5
-
AnX Robotica awarded Gastrointestinal Endoscopy Products agreement with Premier, Inc.
-
Taiwan's Products for Modern Households Focus on Customization, Health, and Wellbeing
-
BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL
-
Global Times: Doctor and warrior: Chinese MMA fighter Shi Ming rises to fame for contrasting identities
-
WSPN Partners with Fractal to Expand Stablecoin Access on Bitcoin
-
The revival of Notre-Dame witnesses the value of cultural exchange and mutual learning: Global Times editorial
-
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
-
At Harvard Symposium, Squirrel Ai's Dr. Joleen Liang Forecasts the Next Chapter in AI-Driven Education
-
Global Total Semiconductor Equipment Sales Forecast to Reach a Record of $139 Billion in 2026, SEMI Reports
-
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
-
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagn
-
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
-
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
-
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
-
SK Life Science, Inc. Presents XCOPRI® (cenobamate tablets) CV Data at the AES 2024 Annual Meeting Showing a Deeper Understanding of Cenobamate's Dual Mechanism of Action
-
WTCH 24 - Countless historical results and a new superpower emerged
-
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
-
Apple Sued for Knowingly Hosting Child Sexual Abuse Material on Its Products, Failing to Protect Survivors
-
Global Times: People's Daily article says favorable conditions for China's economic development remain unchanged
-
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
-
Studies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions
-
Max Stock Limited: Immediate report of changes to interested party holdings
-
National Press Club: Family Of Austin Tice Available for Interviews at St. John's Church
-
Nanning: A Colorful City of Cultural Diversity
-
The Best Christmas Gift Ideas for 2024: Transformative Skincare with a Special Holiday Twist
-
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
-
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
-
PRIME MINISTER OF MONGOLIA MAKES HISTORIC VISIT TO MIDDLE EAST
-
Global Times: Clay Figure Zhang's works naturally reflect spiritual state of the times
-
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
-
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
-
MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US Environmental Protection Agency
-
Building Homes for Heroes Gifts 400th Home, Marking Historic Achievement in Veteran and First Responder Support
-
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relaps
-
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeti
-
Ethara: THE ART OF CURATING THE ABU DHABI GRAND PRIX HOSPITALITY EXPERIENCE
-
Researchers Report New Opportunities to Improve Quality of Life for People with Non-Malignant Blood Disorders
-
Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease
-
Blokees' Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
-
Research Shows How Lifestyle Factors and Diet Affect Hematologic Care
-
New Research from Children's Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly Diagnosed Children with B-cell Acute Lymphoblastic Leukemia
-
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
